Open AccessSARS‐COV ‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder
Author(s) -
Johnsson Magnus,
Asztely Fredrik,
Hejnebo Susanne,
Axelsson Markus,
Malmeström Clas,
Olausson Torbjörn,
Lycke Jan
Publication year - 2022
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.51609
Subject(s) - medicine , myelin oligodendrocyte glycoprotein , optic neuritis , multiple sclerosis , encephalomyelitis , immunology , demyelinating disorder , myelitis , pathology , experimental autoimmune encephalomyelitis , psychiatry , spinal cord
Abstract SARS‐COV‐2 frequently cause neurological disorders and is sometimes associated with onset of autoimmune diseases affecting the nervous system. Over recent years, a rare but distinct diagnosis designated myelin oligodendrocyte glycoprotein‐associated disorder (MOGAD) has been recognized in patients with attacks of optic neuritis, myelitis, or encephalomyelitis and increased levels of anti‐MOG antibodies. The cause of MOGAD is unknown. However, there have been reports of single cases of MOGAD in patients with Covid‐19 infection. We report a series of SARS‐CoV‐2 positive patients that developed MOGAD, but a homology search did not support a cross‐reactive immune response to SARS‐CoV‐2 spike‐protein and MOG.